Richard K. Prins Sells 10,000 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPHGet Free Report) Director Richard K. Prins sold 10,000 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $43.77, for a total transaction of $437,700.00. Following the transaction, the director now owns 30,471 shares of the company’s stock, valued at approximately $1,333,715.67. This represents a 24.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $44.50 on Friday. Amphastar Pharmaceuticals, Inc. has a 52-week low of $36.56 and a 52-week high of $65.92. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm’s fifty day moving average is $47.22 and its 200 day moving average is $44.62. The company has a market cap of $2.14 billion, a price-to-earnings ratio of 14.83, a PEG ratio of 0.87 and a beta of 0.78.

Analyst Ratings Changes

Several analysts have commented on the stock. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target on the stock. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $60.33.

Get Our Latest Report on AMPH

Institutional Trading of Amphastar Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC grew its position in Amphastar Pharmaceuticals by 70.0% in the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after acquiring an additional 273 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after purchasing an additional 398 shares during the period. Innealta Capital LLC bought a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at approximately $55,000. Blue Trust Inc. raised its holdings in Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after buying an additional 309 shares during the period. Finally, Asset Management One Co. Ltd. bought a new stake in Amphastar Pharmaceuticals in the third quarter worth $78,000. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

About Amphastar Pharmaceuticals

(Get Free Report)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

Recommended Stories

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.